Mercedes Pérez-Escavy

Mercedes Pérez-Escavy

Auto-generated profile, based on publicly available information

Mercedes Pérez-Escavy

Genitourinary and Cellular and Molecular Oncology Group, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2026 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
EMEster Munera-Maravilla
Ester Munera-Maravilla
MPMercedes Pérez-Escavy
Mercedes Pérez-Escavy
CRCarolina Rubio
Carolina Rubio
CSCristina Segovia
Cristina Segovia
ILIris Lodewijk
Iris Lodewijk
CSCristian Suárez-Cabrera
Cristian Suárez-Cabrera
Background: Bladder cancer (BC) remains a major clinical challenge owing to its high recurrence, limited treatment options, and molecular heterogeneity. Despite recent therapeutic advances, prognosis remains poor and resistance to treatment is common, underscoring the need for improved experimental models to study tumorigenesis and therapeutic response. A critical obstacle in advanced BC research is the scarcity of in vivo models that accurately replicate invasive and metastatic behavior and serve as robust preclinical tools for evaluating new therapies, especially in immunocompetent settings. Methods: To assess how the cell of origin and specific driver genes influence bladder tumorigenesis and subtype specification, we engineered four genetically modified mouse models of advanced BC. Two combinations of tumor suppressor genes—either Pten and Trp53 , or Pten , Trp53 , Rb1 , and Rbl1 — were targeted either basal or suprabasal urothelial cells via intravesical Cre-adenovirus delivery. From tumors arising in these models, we derived multiple cell lines and established syngeneic graft models. Both genetically engineered mouse models and derived mouse cell lines were extensively characterized and transcriptionally compared with advanced human BC and human BC cell lines, and were further utilized as preclinical platforms to evaluate therapeutic responses. Results: Loss of the retinoblastoma gene family reduced cancer-specific survival and was associated with more differentiated carcinomas. In both genetic backgrounds, luminal-derived tumors appeared earlier but displayed fewer metastatic events. Histopathological and transcriptomic analyses revealed that these tumors resemble human basal-squamous and stroma-rich subtypes, sharing regulatory networks and activated signaling pathways with human invasive BC. Tumors lacking retinoblastoma family genes exhibited enhanced immune infiltration, reinforcing their value for diverse preclinical applications. To overcome detection and latency limitations, we established syngeneic graft models from tumor-derived cell lines. These models were validated as preclinical platforms, exhibiting therapeutic responses to CDK4/6 inhibition and anti-PD-L1 immunotherapy. Conclusions: These novel mouse models faithfully recapitulate key molecular, histological, and immune features of human invasive BC. They represent versatile and clinically relevant preclinical models for dissecting disease progression mechanisms and evaluating emerging therapeutic strategies within an intact immune environment.

18 July 2025 in bioRxiv
Verified
Preprint
Open access
EMEster Munera-Maravilla
Ester Munera-Maravilla
MPMercedes Pérez-Escavy
Mercedes Pérez-Escavy
CRCarolina Rubio
Carolina Rubio
CACristina Segovia de Andrés
Cristina Segovia de Andrés
ILIris Lodewijk
Iris Lodewijk
CSCristian Suárez-Cabrera
Cristian Suárez-Cabrera
Bladder cancer (BC) remains a major clinical challenge owing to its high recurrence, limited treatment options, and molecular heterogeneity. Despite recent therapeutic advances, prognosis remains poor, and resistance is frequent, underscoring the need for improved experimental models to study tumorigenesis and therapeutic response. A key limitation of advanced BC research is the scarcity of in vivo models that accurately reflect invasive disease, with even fewer capturing the complexity of metastasis. To investigate how the cell-of-origin and specific combinations of driver mutations influence in bladder tumorigenesis, we developed and characterized four genetically engineered mouse models of advanced BC by targeting two combinations of tumor suppressor genes ( Pten and Trp53 , or Pten , Trp53 , Rb1 , and Rbl1 ) in basal or suprabasal urothelial cells through intravesical of Cre-adenovirus delivery. Loss of the retinoblastoma family reduced cancer-specific survival and was associated with more differentiated carcinomas. In both genetic backgrounds, luminal-derived tumors developed earlier but showed fewer metastatic events. Histopathological and transcriptomic analyses revealed that these tumors resemble human basal-squamous and stroma-rich subtypes, sharing regulatory networks and activated signaling pathways with human invasive tumors. Notably, tumors lacking retinoblastoma family genes exhibited increased immune infiltration, reinforcing the value of these models for diverse preclinical applications. To overcome detection and latency limitations, we established tumor-derived cell lines and generated syngeneic graft models. These were validated as preclinical platforms, exhibiting therapeutic responses to CDK4/6 inhibition and anti-PD-L1 immunotherapy. Our findings highlight the value of these novel models for studying BC progression and evaluating emerging therapeutic strategies in immunocompetent settings.